New guidelines answer questions in the hormone-replacement debate

Healthcare researchers say it’s critical to get more women, Black and Latino participants in clinical trials. It can be done, but researchers and institutions must make the effort.

Improving patient monitoring through care-at-home services could help reduce maternal mortality, they say.

Opill will be available in stores and online in the first quarter of 2024.

If approved, Perrigo’s Opill could be the first-ever nonprescription birth control pill.

Brexafemme is a non-azole oral antifungal now approved to both treat and prevent recurrent yeast infections in women.

The approval extends the use of Liletta for an additional two years. It is the only hormonal IUD approved for continuous use up to eight years.